S Leikin, I Bernstein, A Evans, J Finklestein, R Hittle, M Klemperer
{"title":"阿霉素(NSC-123127)联合DTIC (NSC-45388)在晚期IV期神经母细胞瘤患儿中的应用","authors":"S Leikin, I Bernstein, A Evans, J Finklestein, R Hittle, M Klemperer","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Adriamycin and DTIC were used in combination because of their reported effectiveness in neuroblastoma when administered as single agents and because of the poor survival rate of patients with this malignancy in its disseminated stage. Eighteen patients with previously treated stage IV neuroblastoma received this combination chemotherapy every 21 days. Two to eight courses were administered. Two partial and no complete remissions were seen. Mild to moderate gastrointestinal and hematologic toxicity was observed.</p>","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 5","pages":"1015-8"},"PeriodicalIF":0.0000,"publicationDate":"1975-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Use of combination adriamycin (NSC-123127) and DTIC (NSC-45388) in children with advanced stage IV neuroblastoma.\",\"authors\":\"S Leikin, I Bernstein, A Evans, J Finklestein, R Hittle, M Klemperer\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Adriamycin and DTIC were used in combination because of their reported effectiveness in neuroblastoma when administered as single agents and because of the poor survival rate of patients with this malignancy in its disseminated stage. Eighteen patients with previously treated stage IV neuroblastoma received this combination chemotherapy every 21 days. Two to eight courses were administered. Two partial and no complete remissions were seen. Mild to moderate gastrointestinal and hematologic toxicity was observed.</p>\",\"PeriodicalId\":9510,\"journal\":{\"name\":\"Cancer chemotherapy reports\",\"volume\":\"59 5\",\"pages\":\"1015-8\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1975-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer chemotherapy reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer chemotherapy reports","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Use of combination adriamycin (NSC-123127) and DTIC (NSC-45388) in children with advanced stage IV neuroblastoma.
Adriamycin and DTIC were used in combination because of their reported effectiveness in neuroblastoma when administered as single agents and because of the poor survival rate of patients with this malignancy in its disseminated stage. Eighteen patients with previously treated stage IV neuroblastoma received this combination chemotherapy every 21 days. Two to eight courses were administered. Two partial and no complete remissions were seen. Mild to moderate gastrointestinal and hematologic toxicity was observed.
分享
京公网安备 11010802042870号
京ICP备2023020795号-1
求助内容：
应助结果提醒方式：
扫码关注我们
